tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
US Market
KALV
KalVista Pharmaceuticals
Overview
Analyst Forecasts
AI Stock Analysis
News & Insights
Financials
Dividends
Technical Analysis
Options
Chart
Earnings
Ownership
Stock Buybacks
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

KalVista Pharmaceuticals (KALV) Stock News & Sentiment

Compare
410 Followers
Buy Rating for KalVista Pharmaceuticals Driven by Strategic Positioning and Market Potential of Sebetralstat
Premium
Ratings
Buy Rating for KalVista Pharmaceuticals Driven by Strategic Positioning and Market Potential of Sebetralstat
8d ago
KALV
Buy Rating for KalVista Pharmaceuticals: Strong Regulatory Progress and Market Potential for Sebetralstat
Premium
Ratings
Buy Rating for KalVista Pharmaceuticals: Strong Regulatory Progress and Market Potential for Sebetralstat
8d ago
KALV
Promising Potential of Sebetralstat: A Game-Changer in Hereditary Angioedema Treatment
Premium
Ratings
Promising Potential of Sebetralstat: A Game-Changer in Hereditary Angioedema Treatment
11d ago
KALV
Buy Rating for KalVista Pharmaceuticals Driven by Anticipated FDA Approval and Strong Market Position
Premium
Ratings
Buy Rating for KalVista Pharmaceuticals Driven by Anticipated FDA Approval and Strong Market Position
11d ago
KALV
KalVista Pharmaceuticals Advances Sebetralstat for HAE
Premium
Company Announcements
KalVista Pharmaceuticals Advances Sebetralstat for HAE
12d ago
KALV
KalVista Pharmaceuticals: Strategic Preparations and Financial Strength Underpin Buy Rating Amid Anticipated Sebetralstat Approval
Premium
Ratings
KalVista Pharmaceuticals: Strategic Preparations and Financial Strength Underpin Buy Rating Amid Anticipated Sebetralstat Approval
12d ago
KALV
Buy Rating for KalVista Pharmaceuticals Driven by Strong Financials and Promising Ekterly Launch
Premium
Ratings
Buy Rating for KalVista Pharmaceuticals Driven by Strong Financials and Promising Ekterly Launch
12d ago
KALV
More KALV News >

KALV News on the Web

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
Yahoo Finance
Neutral
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo Finance
Neutral
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Yahoo Finance
Neutral
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
Yahoo Finance
Neutral
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
Yahoo Finance
Neutral
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo Finance
Neutral
Optimistic Buy Rating for KalVista Pharmaceuticals Amid Promising Launch of Sebetralstat
TipRanks News
Bullish
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
Yahoo Finance
Neutral

News Score - Last 7 Days

Neutral
KALV
Sector Average
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
This Week59%
Sector Average58%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is KALV’s Media Buzz Sentiment?
Currently, no data Available
What is KALV’s weekly average amount of articles?
Currently, no data Available
What is KALV’s News Sentiment?
59% of articles about KALV were positive this week, compared to its sector average of 58%.
    Healthcare Stocks that are Trending in the News
    PLXProtalix
    DVAXDynavax
    OGNOrganon
    IMVTImmunovant
    RBOTVicarious Surgical
    Showing the stocks with the most bullish news sentiment over the past week

    Become an Expert with TipRanks Premium

    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis
    Subscribe NowSee Plans & Pricing